Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2022 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Rating) issued an update on its FY 2022 earnings guidance on Tuesday morning. The company provided EPS guidance of $7.86-$7.86 for the period. The company issued revenue guidance of $51.64 billion-$51.64 billion, compared to the consensus revenue estimate of $51.59 billion.

BAYRY stock opened at $17.77 on Tuesday. The stock has a 50-day moving average price of $17.06 and a two-hundred day moving average price of $15.23. Bayer Aktiengesellschaft has a 12-month low of $12.45 and a 12-month high of $18.45. The company has a current ratio of 1.11, a quick ratio of 0.72 and a debt-to-equity ratio of 1.10. The company has a market cap of $69.83 billion, a PE ratio of 8.30, a price-to-earnings-growth ratio of 2.28 and a beta of 1.11.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Rating) last posted its quarterly earnings results on Tuesday, March 1st. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.10. The firm had revenue of $12.72 billion during the quarter, compared to the consensus estimate of $11.68 billion. Bayer Aktiengesellschaft had a return on equity of 22.39% and a net margin of 4.29%. Equities analysts forecast that Bayer Aktiengesellschaft will post 1.97 EPS for the current fiscal year.

The business also recently disclosed a dividend, which was paid on Monday, May 16th. Shareholders of record on Tuesday, May 3rd were paid a dividend of $0.3693 per share. This represents a dividend yield of 2.26%. The ex-dividend date was Monday, May 2nd. Bayer Aktiengesellschaft’s dividend payout ratio is presently 59.32%.

BAYRY has been the topic of a number of recent research reports. Citigroup upgraded Bayer Aktiengesellschaft from a neutral rating to a buy rating in a research note on Monday, January 31st. UBS Group boosted their price objective on Bayer Aktiengesellschaft from €90.00 ($96.77) to €96.00 ($103.23) and gave the stock a buy rating in a research note on Thursday, May 19th. Jefferies Financial Group began coverage on Bayer Aktiengesellschaft in a research note on Monday, March 14th. They set a buy rating on the stock. Barclays boosted their price target on Bayer Aktiengesellschaft from €85.00 ($91.40) to €90.00 ($96.77) and gave the stock an overweight rating in a research note on Wednesday, May 11th. Finally, Morgan Stanley boosted their price target on Bayer Aktiengesellschaft from €77.00 ($82.80) to €83.00 ($89.25) and gave the stock an overweight rating in a research note on Monday, April 25th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Buy and an average target price of $82.25.

Bayer Aktiengesellschaft Company Profile (Get Rating)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Further Reading

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with's FREE daily email newsletter.